8-K: Klotho Neurosciences Terminates SkyBell Acquisition, Secures $500,000 in New Preferred Stock Funding

Klotho Neurosciences, Inc. announced the mutual termination of its Share Exchange Agreement to acquire SB Security Holdings, LLC from SkyBell Technologies, Inc., while simultaneously disclosing a new $500,000 private placement of Series B Preferred Stock.

Summary

• Klotho Neurosciences, Inc. (Klotho) and Skybell Technologies, Inc. (SkyBell) mutually agreed to terminate the Share Exchange Agreement, originally dated March 26, 2025, which aimed for Klotho to acquire SkyBell's subsidiary, SB Security Holdings, LLC (SBSH).
• The termination also includes the Series A Preferred Stock Term Sheet, dated May 5, 2025, under which Klotho was to issue 84,000 shares of Series A Preferred Stock to SBSH for $8,400,000.
• Neither party will incur any liability as a result of the termination, and a mutual release of all claims related to the agreements has been executed.
• On June 9, 2025, Klotho entered into a Stock Purchase Agreement to sell Series B Preferred Stock for a total purchase price of $500,000.
• The Series B Preferred Stock is convertible into shares of Klotho's Common Stock once a registration statement for the underlying Common Stock is declared effective by the SEC.
• This sale was conducted as an unregistered offering under Section 4(2) of the Securities Act of 1933, based on the purchaser's investment intent and financial sophistication.

Sentiment

Score: 4

Explanation: The termination of a significant acquisition is a negative event, indicating a failed strategic move and loss of potential funding. However, the immediate $500,000 capital raise and the mutual, no-liability termination mitigate the negative impact somewhat, preventing a lower score.

Positives

• The termination of the Share Exchange Agreement and Term Sheet was mutual, with no liability incurred by either Klotho or SkyBell.
• A mutual release of all past, present, and future claims related to the terminated agreements provides legal clarity and prevents future litigation.
• Klotho successfully secured $500,000 through the sale of Series B Preferred Stock, providing new capital.
• The Series B Preferred Stock sale was made to a sophisticated investor for investment purposes, indicating a targeted capital infusion.

Negatives

• The termination of the Share Exchange Agreement means Klotho will not acquire SB Security Holdings, LLC, potentially altering its strategic growth plans.
• Klotho will not receive the $8,400,000 in consideration from the previously contemplated Series A Preferred Stock transaction with SBSH.
• The company's Nasdaq symbol (KLTO) and warrants (KLTOW) remain unchanged, indicating the planned acquisition and potential rebranding (e.g., using SKYB symbol) will not proceed as initially envisioned for Klotho.

Risks

• The Series B Preferred Stock is convertible into common stock only after a registration statement is declared effective by the SEC, introducing a potential delay or uncertainty for the investor regarding liquidity.
• The company's ability to successfully integrate new capital and pursue alternative growth strategies following the terminated acquisition remains a factor.
• The termination of a significant acquisition could raise questions about the company's strategic direction or ability to execute large transactions.

Future Outlook

The Series B Preferred Stock is convertible into shares of Klotho's Common Stock at any time after a registration statement for the Common Stock is declared effective by the Securities and Exchange Commission. Klotho also agrees to use its best efforts to have the previously reserved Nasdaq symbol SKYB assigned to SBSH.

Management Comments

• Klotho Neurosciences, Inc. mutually agreed with Skybell Technologies, Inc, to terminate the March 26, 2025 Share Exchange Agreement to acquire its SB Security Holdings, LLC subsidiary.
• Neither party will incur any liability as a result of the termination.
• Klotho hereby agrees to use its best efforts to have the previously reserved Nasdaq symbol SKYB assigned to SBSH, including by means of instructing Donohoe Advisory Associates LLC to assign the symbol to SBSH.

Industry Context

Klotho Neurosciences operates in the neuroscience sector, while SkyBell Technologies and its subsidiary SBSH are in security technology. The termination of this acquisition suggests a strategic divergence or an inability to find common ground for integration between these distinct industry segments. The new capital raise indicates Klotho is seeking to fund its operations independently following the failed merger.

Comparison to Industry Standards

• NA

Legal Proceedings

• The Termination and Release Agreement includes a mutual release of all past, present, direct, indirect, and derivative liabilities, actions, causes of action, claims, and damages related to the Share Exchange Agreement, the Term Sheet, and the proposed transactions. This effectively prevents future legal proceedings arising from these terminated agreements.

Related Party Transactions

• The sale of Series B Preferred Stock was made based on a "pre-existing relationship between the Registrant and the purchaser," though the purchaser is not explicitly identified as a related party in the filing.

Stakeholder Impact

• Shareholders: The termination of the acquisition could impact the company's long-term growth strategy and valuation. The new Series B Preferred Stock introduces a new class of equity and potential future dilution upon conversion.
• Employees: The failure of the acquisition means no integration with SBSH, potentially affecting future employment opportunities or organizational structure changes that would have resulted from the merger.
• Creditors: The $500,000 capital raise provides additional liquidity, which could be viewed positively by creditors.

Next Steps

• Klotho Neurosciences, Inc. needs to file a registration statement with the SEC for the Common Stock into which the Series B Preferred Stock is convertible.
• Klotho will use its best efforts to have the previously reserved Nasdaq symbol SKYB assigned to SBSH.

Key Dates

Keywords

Klotho Neurosciences, Skybell Technologies, SB Security Holdings, Share Exchange Agreement, Series B Preferred Stock, Capital Raise, SEC Filing, Form 8-K, Acquisition Termination, Private Placement, Unregistered Securities, Neurosciences, Security Technology